alexa Validation Of A Novel Therapeutic Target For Targeted Radionuclide-antibody Therapy Of Malignant Pleural Effusion
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

Global Summit on Oncology & Cancer
May 25-27, 2017 Osaka, Japan

Jaecheong Lim
Korea Atomic Energy Research Institute, South Korea
ScientificTracks Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956-C1-099
Malignant pleural effusion (MPE) is a frequent complication in patients who have a broad range of advanced cancers, including lymphomas and carcinomas of the lung, breast, gastrointestinal tract, and ovaries, and portends a worse prognosis in these cancers. Among these cancers, the most common causes for MPE is lung cancer (37.5%). Treatment of MPE consists of tube thoracostomy and intrapleural administration of sclerosing agents, including chemicals, such as talc; antibiotics, such as tetracycline, doxycycline, and minocycline; and antineoplastic agents, such as cisplatin, bleomycin, doxorubicin, and mitomycin. However, in many cases, MPE is refractory to these treatments because those therapeutic agents cannot treat the cancer cells. Therefore, we focused on searching a novel therapeutic target for developing a targeted radionuclide-antibody therapy of malignant pleural effusion metastasized from lung cancer. As a result, we selected a membrane receptor which is overexpressed on the MPE cell lines, and a chimeric-antibody binding with the receptor were prepared by using phage display technology. The antibody were radiolabeled with Lu-177, and in vitro & in vivo pharmacokinetic characteristics were evaluated. Therapeutic efficacy of the radiolabeled-chimeric antibody was also evaluated using MPE animal models.

Jaecheong Lim, a Doctor of Veterinary Medicine (PhD-DVM), is a Senior Researcher of the Radioisotope Research Division in the Korea Atomic Energy Research Institute. He is currently developing radiolabeling technologies and radiolabeled compounds for the treatment of cancers, and published more than 20 papers in related journals.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version